William Blair Forecasts Lower Earnings for Cooper Companies

The Cooper Companies, Inc. (NASDAQ:COO) – Equities research analysts at William Blair lowered their Q1 2025 earnings estimates for Cooper Companies in a report released on Monday, December 9th. William Blair analyst M. Andrew now expects that the medical device company will post earnings per share of $0.92 for the quarter, down from their previous estimate of $0.95. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. William Blair also issued estimates for Cooper Companies’ Q2 2025 earnings at $0.94 EPS, Q3 2025 earnings at $1.04 EPS and FY2025 earnings at $3.98 EPS.

Several other brokerages have also weighed in on COO. Robert W. Baird boosted their price objective on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, August 29th. StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday. Stifel Nicolaus reiterated a “buy” rating and set a $115.00 price objective (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Piper Sandler lifted their target price on Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Finally, Morgan Stanley dropped their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $117.00.

Cooper Companies Stock Down 1.9 %

Shares of NASDAQ COO opened at $94.85 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. Cooper Companies has a 1 year low of $84.76 and a 1 year high of $112.38. The stock’s 50-day simple moving average is $103.49 and its 200-day simple moving average is $98.87. The firm has a market cap of $18.93 billion, a price-to-earnings ratio of 48.64, a PEG ratio of 2.52 and a beta of 0.97.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.04. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. Cooper Companies’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.87 EPS.

Insiders Place Their Bets

In other news, CEO Albert G. White III sold 114,992 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total value of $12,710,065.76. Following the completion of the sale, the chief executive officer now owns 165,273 shares in the company, valued at $18,267,624.69. This represents a 41.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. raised its stake in shares of Cooper Companies by 480.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 937,806 shares of the medical device company’s stock worth $81,870,000 after purchasing an additional 776,140 shares in the last quarter. Victory Capital Management Inc. grew its position in Cooper Companies by 23.0% in the third quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock worth $435,856,000 after acquiring an additional 737,726 shares in the last quarter. Magnetar Financial LLC bought a new stake in Cooper Companies in the second quarter worth approximately $63,822,000. TD Asset Management Inc bought a new position in shares of Cooper Companies during the 2nd quarter valued at $53,045,000. Finally, Impax Asset Management Group plc boosted its holdings in Cooper Companies by 31.0% in the second quarter. Impax Asset Management Group plc now owns 2,359,798 shares of the medical device company’s stock worth $205,511,000 after purchasing an additional 558,886 shares in the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.